The effect of CYP2C19 gene polymorphism on clinical outcomes in patients with CAD receiving antiplatelet therapy

被引：0
|
作者：
Liu, W. [1 ]
Xi, Z. W. [1 ]
Zhou, Y. J. [1 ]
机构：
[1] Beijing Anzhen Hosp, Caridiol, Beijing, Peoples R China
来源：
EUROPEAN HEART JOURNAL | 2017年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P4010
引用
收藏
页码：837 / 837
页数：1
相关论文
共 50 条
  • [41] The effect of CYP2C19 and CYP2C9 polymorphism on the pharmacodynamics of clopidogrel
    Jiang, Juanjuan
    Tian, Lei
    Han, Lulu
    Yan, Yan
    Huang, Yiling
    Liu, Hong
    Xie, Shuang
    Li, Yishi
    CARDIOLOGY, 2011, 120 : 30 - 31
  • [42] Impact of CYP2C19 Polymorphisms on the Antiplatelet Effect of Clopidogrel in an Actual Clinical Setting in Japan
    Jinnai, Toshikazu
    Horiuchi, Hisanori
    Makiyama, Takeru
    Tazaki, Junichi
    Tada, Tomohisa
    Akao, Masaharu
    Ono, Koh
    Hoshino, Kozo
    Naruse, Yumiko
    Takahashi, Kanako
    Watanabe, Haruyo
    Kita, Toru
    Kimura, Takeshi
    CIRCULATION JOURNAL, 2009, 73 (08) : 1498 - 1503
  • [43] Clinical Outcomes and Sustainability of Using CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention
    Lee, Craig R.
    Sriramoju, Vindhya B.
    Cervantes, Alexandra
    Howell, Lucius A.
    Varunok, Nicholas
    Madan, Shivanshu
    Hamrick, Kasey
    Polasek, Melissa J.
    Lee, John Andrew
    Clarke, Megan
    Cicci, Jonathan D.
    Weck, Karen E.
    Stouffer, George A.
    CIRCULATION-GENOMIC AND PRECISION MEDICINE, 2018, 11 (04): : e002069
  • [44] Impact of CYP2C19 Polymorphisms on Clinical Outcomes and Antiplatelet Potency of Clopidogrel in Caucasian Poststroke Survivors
    Tomek, Ales
    Mat'oska, Vaclav
    Frydmanova, Alena
    Magerova, Hana
    Sramek, Martin
    Paulasova-Schwabova, Jaroslava
    Ruzickova, Tereza
    Jansky, Petr
    Sarbochova, Ivana
    Hadacova, Ivana
    Kaplan, Vojtech
    Lacinova, Zuzana
    Taborsky, Ludek
    Serebruany, Victor
    AMERICAN JOURNAL OF THERAPEUTICS, 2018, 25 (02) : E202 - E212
  • [45] DISTRIBUTION OF THE CYP2C19*2, CYP2C19*3 AND CYP2C19*4 GENE VARIANTS IN A ROMANIAN POPULATION
    Buzoianu, A. D.
    Trifa, A. P.
    Popp, R. A.
    Militaru, C. F.
    Bocsan, C., I
    Popp, I., V
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2009, 105 : 80 - 80
  • [46] The Impact of CYP2C19 Polymorphisms on Clinical Outcomes of the Patients Treated with Clopidogrel
    Lee, Y.
    Kim, M.
    Kim, H.
    Lee, E.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2015, 17 (06): : 760 - 760
  • [47] CYP2C19*2 polymorphism in Polish peptic ulcer patients
    Aleksandra Sałagacka-Kubiak
    Marta Żebrowska-Nawrocka
    Agnieszka Jeleń
    Marek Mirowski
    Ewa Balcerczak
    Pharmacological Reports, 2019, 71 : 272 - 275
  • [48] CYP2C19*2 polymorphism in Polish peptic ulcer patients
    Salagacka-Kubiak, Aleksandra
    Zebrowska-Nawrocka, Marta
    Jelen, Agnieszka
    Mirowski, Marek
    Balcerczak, Ewa
    PHARMACOLOGICAL REPORTS, 2019, 71 (02) : 272 - 275
  • [49] Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy
    Yu Wu
    Yilun Zhou
    Yuesong Pan
    Xingquan Zhao
    Liping Liu
    David Wang
    Chunxue Wang
    Hao Li
    S. Claiborne Johnston
    Xia Meng
    Yilong Wang
    Yongjun Wang
    The Pharmacogenomics Journal, 2018, 18 : 713 - 720
  • [50] The CYP2C19 gene polymorphism and anti-platelet effect in patients with CHD who treated with PPIs
    Yu, Lianying
    Sha, Weihong
    Wang, Qiyi
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 316 - 316
12345